We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gentium SpA | LSE:GENT | London | Common Stock |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0 | - |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | USD |
Gentium SpA (GENT) Share Charts1 Year Gentium SpA Chart |
|
1 Month Gentium SpA Chart |
Intraday Gentium SpA Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 06/12/2006 | 18:46 | A Day in the Life of a Gentleman Armchair Investor | 40 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 06/11/2006 10:58 by grupo guitarlumber its interesting sometimes when one asks a simple questionsuddenly there's a frenzy and then all is still. i remember many years ago catching a barracuda, only to have it quickly disappear in a feeding frenzy of blood scented mindless barracudas and then all was still with me left with just the a small share. |
Posted at 06/11/2006 10:25 by grupo guitarlumber bprgHambi - 6 Nov'06 - 10:23 - 11250 of 11250 has anyone noticed that the 74.5p comes from a NPV analysis whereas in the bn the discoutned cash flow analysis gives a market valuation range of 102-117p per share (page 12) |
Posted at 06/11/2006 10:14 by grupo guitarlumber anotherguru - 6 Nov'06 - 10:11 - 3306 of 3308BioProgress AiM / Pharmaceuticals & Biotechnology / BPRG.L Bridgewell Limited acts as broker and Nomad to BioProgress, and makes markets in company's equity airPharma acquisition, SoluPol deal & fund raising Over the last few months, BioProgress has continued to make substantial progress in its new business strategy. This has been further bolstered by recent acquisition of the airPharma assets, which will contribute to branded product strategy and to the Rx-OTC switch strategy, which management started to pursue with the acquisitions of Dexo and Segix. This airPharma acquisition, in conjunction with the first BioProgress enabling technology deal for SoluPol, means that BioProgress is now expected to show substantial profit growth over the next few years. In light of these upgrades to our forecasts, we are revising our market valuation range to £125.5m- £172.0m or 74.5p-102.2p per share. We therefore retain our Buy rating. |
Posted at 02/11/2006 13:16 by grupo guitarlumber SocGen Lowers Sanofi Target Price To EUR85.6 Thursday, November 02, 2006 5:49:39 AM ET Dow Jones Newswires 0925 GMT [Dow Jones] Societe Generale lowers Sanofi-Aventis (SNY) target price to EUR85.6 from EUR90 based on a higher discount rate to take into account "risks and threats," following 3Q results. Target price is still substantially higher than the current share price, bank notes. Keeps its buy rating. Shares -0.8% at EUR66.20.(ACH) |
Posted at 02/11/2006 08:41 by grupo guitarlumber It appears to be a down Day today.i've started to wonder whether there's a correlation between temperture drops and share price drops. The NE Wind doeth blow and we shall have snow. Sunny and Blue Skys today however. Feel like snuggling down into the Armchair. Yet must pop out into the artic weather to buy and plant some Kiwi Fruit Climbers. Enjoy your Day I'll look in later. |
Posted at 01/11/2006 12:30 by grupo guitarlumber silly boy, thus is a sterling share.bought some sanofi aventis shares for 67 euros in the hope it will touch 80 euros Real risky, i hope i don't get a heart attack. |
Posted at 01/11/2006 11:44 by grupo guitarlumber Now the logs are on the fire and the beer cans are set up.i wonder whether Sanofi Aventis is really worth buying? Cheuvreux Cuts Sanofi Target To EUR80.00 Wednesday, November 01, 2006 6:19:58 AM ET Dow Jones Newswires 1006 GMT [Dow Jones]--Cheuvreux lowers Sanofi-Aventis's (SNY) target price to EUR80.00 from EUR83.00 as the company's sales could be impacted by "the recent string of cost-containment measures in Europe, most notably in Germany and in France." Yet it says "the evaluation document of Acomplia in Europe leads us to optimism for next approval in the US." Shares stable at EUR66.60. (GAM) |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
